Clene Operating Margin from 2010 to 2024

CLNNW Stock  USD 0.05  0.02  58.84%   
Clene Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin will likely drop to -65.09 in 2024.
Check Clene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clene's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 1.5 M or Interest Expense of 4.8 M, as well as many indicators such as Price To Sales Ratio of 45.2, Dividend Yield of 0.0 or PTB Ratio of 2.21. Clene financial statements analysis is a perfect complement when working with Clene Valuation or Volatility modules.
  
Check out the analysis of Clene Correlation against competitors.

Latest Clene's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Clene Inc over the last few years. It is Clene's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Clene's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (81.22) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Clene Operating Margin Regression Statistics

Arithmetic Mean(79.57)
Coefficient Of Variation(11.48)
Mean Deviation6.53
Median(82.54)
Standard Deviation9.13
Sample Variance83.42
Range33.8473
R-Value0.45
Mean Square Error71.44
R-Squared0.20
Significance0.09
Slope0.92
Total Sum of Squares1,168

Clene Operating Margin History

2024 -65.09
2023 -61.99
2022 -95.84
2021 -62.62

About Clene Financial Statements

Clene investors use historical fundamental indicators, such as Clene's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Clene. Please read more on our technical analysis and fundamental analysis pages.
Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The companys products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc is traded on NASDAQ Exchange in the United States.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Clene Stock Analysis

When running Clene's price analysis, check to measure Clene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clene is operating at the current time. Most of Clene's value examination focuses on studying past and present price action to predict the probability of Clene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clene's price. Additionally, you may evaluate how the addition of Clene to your portfolios can decrease your overall portfolio volatility.